Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17921241 | 0.89 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL15732871 | 0.88 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL14062050 | 0.87 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL15732982 | 0.87 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL14061812 | 0.87 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL14061592 | 0.86 | DGAT1 (0.82) | DGAT1 | |
| SCHEMBL17875320 | 0.84 | DGAT1 (0.57) | DGAT1 | |
| SCHEMBL14061933 | 0.84 | DGAT1 (0.75) | DGAT1 | |
| SCHEMBL14062124 | 0.83 | DGAT1 (0.80) | DGAT1 | |
| SCHEMBL17921240 | 0.83 | DGAT1 (0.85) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2710013-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-06-29 | — | — | EP | claimed |
| US-9040517-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-05-26 | — | — | US | claimed |
| US-20140378434-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-25 | — | — | US | claimed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540400-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-07-14 | — | — | US | disclosed |
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-07-14 | — | — | US | disclosed |
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-07-14 | — | — | US | disclosed |
| EP-2710013-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-06-29 | — | — | EP | disclosed |
| US-9273069-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140378434-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378434-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378434-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8859536-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859536-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859536-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2710013-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-03-26 | — | — | EP | disclosed |
| US-20140080809-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-03-20 | — | — | US | disclosed |
| WO-2012162129-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885 |
| US-20140378434-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | DGAT1 1/4885 |
| US-20140080809-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.